Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Sees Significant Growth in Short Interest

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 2,570,000 shares, an increase of 16.8% from the February 13th total of 2,200,000 shares. Currently, 2.5% of the company’s stock are short sold. Based on an average daily trading volume, of 916,800 shares, the short-interest ratio is currently 2.8 days.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $25,000. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares in the last quarter. Finally, Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.1 %

NASDAQ:REGN traded down $0.85 during trading hours on Wednesday, hitting $664.11. 129,705 shares of the company traded hands, compared to its average volume of 624,624. Regeneron Pharmaceuticals has a one year low of $642.00 and a one year high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $72.60 billion, a PE ratio of 17.35, a PEG ratio of 2.34 and a beta of 0.27. The firm’s 50-day simple moving average is $692.84 and its 200-day simple moving average is $823.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $11.86 EPS. Equities analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. TD Cowen dropped their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.